Venlafaxine Hydrochloride Extended-Release Capsules USP — Class II drug recall D-0921-2017
Terminated recall by Lucid Pharma LLC, reported 2017-06-28, distributed nationwide. Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.
| Recall number | D-0921-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lucid Pharma LLC, East Brunswick, NJ, United States |
| Recall initiated | 2017-06-01 |
| Classified | 2017-06-16 |
| Reported by FDA | 2017-06-28 |
| Terminated | 2019-09-25 |
| Distributed | Nationwide (US) |
| NDC | 52343-0132-30, 52343-0132-90 |
Product
Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.
Reason for recall
Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0921-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.